Search results
Results from the WOW.Com Content Network
In a study involving over 100 patients, a dual-drug immunotherapy treatment shows impressive results in treating a specific form of colorectal cancer.
Vaccinogen is currently enrolling patients in a confirmatory Phase III clinical study for OncoVAX called ACTIVE that will enroll 550 patients with stage II colon cancer, randomising 1:1 to receive surgery alone or surgery plus OncoVAX (ClinicalTrials.gov identifier NCT02448173 [16]). The Primary Endpoint in this study is the Disease-Free Interval.
Neuvenge is still in preliminary clinical trials and is evolving as of 2011. First Neuvenge trials were performed on patients with metastatic breast, ovarian or colorectal cancer that expressed HER-2 (HER2/neu). Some patients with stable disease after week 48 received an additional "booster" treatment using the identical protocol.
However, immunotherapy is effective against only some types of colorectal cancer. Now, a phase 1 trial has found that a combination of two monoclonal antibodies — botensilimab and balstilimab ...
Dr. Fakih’s research focuses on developmental therapeutics, especially in what pertains to the management of colorectal cancer. Over the last 20+ years, he has developed and completed more than 20 investigator-initiated clinical trials and published more than 250 peer reviewed manuscripts.
Pelareorep clinical development plan is based on drug combinations that can potentially boost each response of pelareorep's mechanism of action, with three development pathways: 1) chemo combinations (direct cell lysis) 2) immunotherapy combinations (adaptive immune response) and; 3) combination with (immunomodulators) IMiDs / targeted therapy ...
In the 2000s, ipilimumab clinical trials were under way on patients with melanoma, renal cell carcinoma, prostate cancers, urothelial carcinoma and ovarian cancer. [50] By 2007, there were two fully human anti CTLA-4 [51] monoclonal antibodies in advanced clinical trials.
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .